Chicken bone marrow mesenchymal stem cells improve lung and distal organ injury

Abstract

Mesenchymal stem cells (MSCs) are associated with pulmonary protection and longevity. We separated chicken bone marrow-derived mesenchymal stem cells (BM-MSCs); investigated whether BM-MSCs can improve lipopolysaccharide (LPS)-induced lung and distal organ injury; and explored the underlying mechanisms. Ninety-six male ICR (6 weeks old) mice were randomly divided into three groups: Sham, LPS, and LPS + MSC groups. The mice were intratracheally injected with 5 mg/kg LPS to induce acute lung injury (ALI). The histopathological severity of injury to the lung, liver, kidney, heart, and aortic tissues was detected. Wet/dry ratio, protein concentrations in bronchoalveolar lavage fluid (BALF), BALF cell counts, inflammatory cytokine levels in serum, inflammatory cytokine gene expression, and oxidative stress-related indicators were detected. In addition, a survival analysis was performed in sixty male ICR mice (6 weeks old, 18–20 g). This study used chicken BM-MSCs, which are easier to obtain and more convenient than other animal or human MSCs, and have MSC-associated properties, such as a colony forming ability, multilineage differentiation potential, and certain phenotypes. BM-MSCs administration significantly improved the survival rate, systemic inflammation, and the histopathological severity of lung, liver, kidney, and aortic injury during ALI. BM-MSCs administration reduced the levels of inflammatory factors in BALF, the infiltration of neutrophils, and oxidative stress injury in lung tissue. In addition, BM-MSCs administration reduced TRL4 and Mdy88 mRNA expression during ALI. Chicken BM-MSCs serve as a potential alternative resource for stem cell therapy and exert a prominent effect on LPS-induced ALI and extrapulmonary injury, in part through TRL4/Mdy88 signaling and inhibition of neutrophil inflammation and oxidative stress injury.

Mesenchymal stromal cell-based therapy in lung diseases; from research to clinic

“…Furthermore, MSCs can reverse the epithelialmesenchymal transition (EMT) process through inhibiting NF-κB and Hedgehog pathways [81]. MSCs can also reduce the expression of both TRL4 and Mdy88 mRNAs [82]. Moreover, MSCs can stimulate the production of anti-inflammatory IL-10 by macrophage cells, and thereby increase the protection against sepsis-associated the ARDS [48,53].…”

Reconstituted Extracellular Vesicles from Human Platelets Decrease Viral Myocarditis in Mice

“…The biologically active cargo of EVs, such as RNA, proteins, carbohydrates, and lipids, have the potential to alter the function of recipient cells. [2][3][4] EVs from certain sources, such as mesenchymal stem cells (MSCs) and adipose tissue from healthy donors, have been shown to have anti-inflammatory effects in in vitro and in vivo disease models; [3,[5][6][7] however, EVs derived from biogenic sources have not yet received approval for use in humans. [8] Blood and plasma transfusions provide trillions of EVs to the recipient and have documented low-risk safety profiles suggesting that they could be good therapies.…”

Fibroblast growth factor 23 inhibits osteogenic differentiation and mineralization of chicken bone marrow mesenchymal stem cells

“…BMSCs have been isolated from many species, including chickens, sheep, cats, dogs, rats, mice, and humans ( Svoradova et al., 2021 ). The directional differentiation of BMSCs was determined by the presence of different stimuli ( Niu et al., 2021 ). BMSC can be used as an avian culture model to better understand osteogenic process due to their easy isolation, and in vitro proliferation ( Eleuteri and Fierabracci, 2019 ).…”